These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 15074591)
1. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Veerareddy PR; Vobalaboina V; Nahid A Pharmazie; 2004 Mar; 59(3):194-7. PubMed ID: 15074591 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of piperine lipid nanospheres. Veerareddy PR; Vobalaboina V Pharmazie; 2008 May; 63(5):352-5. PubMed ID: 18557418 [TBL] [Abstract][Full Text] [Related]
3. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Raay B; Medda S; Mukhopadhyay S; Basu MK Indian J Biochem Biophys; 1999 Aug; 36(4):248-51. PubMed ID: 10650726 [TBL] [Abstract][Full Text] [Related]
4. Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanospheres. Veerareddy PR; Vobalaboina V; Ali N J Drug Target; 2009 Feb; 17(2):140-7. PubMed ID: 19089691 [TBL] [Abstract][Full Text] [Related]
5. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126 [TBL] [Abstract][Full Text] [Related]
6. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Sinha R; Roychoudhury J; Palit P; Ali N Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice. Pal S; Ravindran R; Ali N Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135 [TBL] [Abstract][Full Text] [Related]
8. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains. Bhaumik SK; Paul J; Naskar K; Karmakar S; De T J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930 [TBL] [Abstract][Full Text] [Related]
9. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis. Everlien H; Hockertz S Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050 [TBL] [Abstract][Full Text] [Related]
10. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B. Asad M; Bhattacharya P; Banerjee A; Ali N BMC Infect Dis; 2015 Apr; 15():188. PubMed ID: 25884796 [TBL] [Abstract][Full Text] [Related]
13. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Gangneux JP; Sulahian A; Garin YJ; Derouin F Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278 [TBL] [Abstract][Full Text] [Related]
14. Antileishmanial effect of cisplatin against murine visceral leishmaniasis. Kaur S; Sachdeva H; Dhuria S; Sharma M; Kaur T Parasitol Int; 2010 Mar; 59(1):62-9. PubMed ID: 19853668 [TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity. Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987 [TBL] [Abstract][Full Text] [Related]
16. Liposomal resiquimod for the treatment of Leishmania donovani infection. Peine KJ; Gupta G; Brackman DJ; Papenfuss TL; Ainslie KM; Satoskar AR; Bachelder EM J Antimicrob Chemother; 2014 Jan; 69(1):168-75. PubMed ID: 23956375 [TBL] [Abstract][Full Text] [Related]
17. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Banerjee A; De M; Ali N J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693 [TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Raposo R; Méndez MT; Torrado-Santiago S; Torrado JJ Antimicrob Agents Chemother; 2004 Sep; 48(9):3246-52. PubMed ID: 15328080 [TBL] [Abstract][Full Text] [Related]
19. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes. Kar N; Chakraborty S; De AK; Ghosh S; Bera T Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani. Zhang R; Shang L; Jin H; Ma C; Wu Y; Liu Q; Xia Z; Wei F; Zhu XQ; Gao H Parasitol Res; 2010 Jul; 107(2):475-9. PubMed ID: 20495931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]